 |
 |
GEO help: Mouse over screen elements for information. |
|
| Status |
Public on Apr 15, 2024 |
| Title |
The role of corticosterone in nevirapine-induced idiosyncratic drug-induced liver injury |
| Organism |
Mus musculus |
| Experiment type |
Expression profiling by high throughput sequencing
|
| Summary |
Nevirapine, an antiretroviral used in the treatment of HIV, is associated with idiosyncratic drug-induced liver injury (IDILI), a potentially life-threatening adverse drug reaction. Its usage has decreased due to this concern, but it is still widely used in lower-resource settings. In general, the mechanisms underlying idiosyncratic drug reactions (IDRs) are poorly understood, but evidence indicates that most are immune-mediated. There is very limited understanding of the early immune response following administration of drugs associated with IDRs, which likely occurs due to reactive metabolite formation. In this work, we aimed to characterize the links between covalent binding of nevirapine, the development of an early immune response, and the subsequent liver injury using a mouse model. We describe initial attempts to characterize an early immune response to nevirapine followed by the discovery that nevirapine induced the release of corticosterone. Corticosterone release was partially associated with the degree of drug covalent binding in the liver, but was also likely mediated by additional mechanisms at higher drug doses. Transcriptomic analysis confirmed metabolic activation, glucocorticoid signaling, and decreased immune activation; GDF-15 also warrants further investigation as part of the immune response to nevirapine. Finally, glucocorticoid blockade preceding the first dose of nevirapine attenuated nevirapine-induced liver injury at 3 weeks, suggesting that acute glucocorticoid signaling is harmful in the context of nevirapine-induced liver injury. This work demonstrates that nevirapine induces acute corticosterone release, which contributes to delayed-onset liver injury. It also has implications for screening drug candidates for IDILI risk and preventing nevirapine-induced IDILI.
|
| |
|
| Overall design |
Primary liver samples from C57BL/6NCrl male mice treated with vehicle or nevirapine (n = 3/group) were used for RNA sequencing
|
| |
|
| Contributor(s) |
Alison J, Samantha Christine S, Jack U |
| Citation(s) |
38636494 |
| |
| Submission date |
Feb 05, 2024 |
| Last update date |
Jul 15, 2024 |
| Contact name |
Jack Uetrecht |
| E-mail(s) |
jack.uetrecht@utoronto.ca
|
| Organization name |
University of Toronto
|
| Department |
Pharmaceutical Sciences
|
| Street address |
144 College Street
|
| City |
Toronto |
| State/province |
ON |
| ZIP/Postal code |
M5S3M2 |
| Country |
Canada |
| |
|
| Platforms (1) |
| GPL24247 |
Illumina NovaSeq 6000 (Mus musculus) |
|
| Samples (6)
|
|
| Relations |
| BioProject |
PRJNA1073404 |
| Supplementary file |
Size |
Download |
File type/resource |
| GSE255038_3h_N_vs_3h_C_DifExp_FPKMs_DESeq2.tsv.gz |
1.5 Mb |
(ftp)(http) |
TSV |
| GSE255038_RAW.tar |
1.2 Mb |
(http)(custom) |
TAR (of TXT) |
SRA Run Selector |
| Raw data are available in SRA |
|
|
|
|
 |
Less...
More...